Armed Cell Acquires Lakefront Preclinical CAR T Portfolio

Company Armed Cell Therapeutics; Lakefront Biotherapeutics Event Type Asset Acquisition (Preclinical Portfolio) Modality CAR-T cell therapy; multi-targeting and armored constructs Asset Preclinical multi-targeting and armed CAR-T portfolio (codes undisclosed) Target Undisclosed Disease Area Non-Hodgkin lymphoma; small-cell lung cancer Summary Lakefront Biotherapeutics completed the sale of…